source
- Replimune secures FDA approval for RP1 therapy in advanced melanoma as Eli Lilly reports strong Q2 earningsReplimune announced that the FDA has granted market approval for its oncolytic immunotherapy RP1, aimed at treating advanced melanoma. The decision follows two earlier rejections and a contentious…
- Study finds cancer patients now wait longer for treatment than a decade agoA new analysis of more than 2.7 million cancer cases shows that the interval between diagnosis and the start of therapy has grown over the past ten years. The researchers examined records from a na…